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The need for a new surveillance approach to understand the clinical outcomes and behaviors of people in care for HIV evolved
from the new challenges for monitoring clinical outcomes in the HAART era, the impact of the epidemic on an increasing
number of areas in the US, and the need for representative data to describe the epidemic and related resource utilization and
needs. The Institute of Medicine recommended that the Centers for Disease Control and Prevention and the Heath Resources
and Services Administration coordinate efforts to survey a random sample of HIV-infected persons in care, in order to more
accurately measure the need for prevention and care services. The Medical Monitoring Project (MMP) was created to meet
these needs. This manuscript describes the evolution and design of MMP, a new nationally representative clinical outcomes
and behavioral surveillance system, and describes how MMP data will be used locally and nationally to identify care and
treatment utilization needs, and to plan for prevention interventions and services.
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INTRODUCTION
HIV/AIDS surveillance programs in all US states collect a core set
of information about persons diagnosed with, living with and
dying from HIV infection and AIDS [1]. Supplemental surveil-
lance projects have historically provided complementary informa-
tion about clinical outcomes of HIV infection and behaviors of
HIV-infected persons. Although these supplemental surveillance
activities have been instrumental in providing additional in-
formation for describing the epidemic, the utility of these
surveillance projects, which were started in 1990, has become
progressively limited over time.
The Medical Monitoring Project (MMP) arose out of a need for
a nationally representative, population-based surveillance system
to assess behaviors, clinical outcomes, and the quality of care for
persons with HIV infection who are receiving care. MMP is
a surveillance system which collects behavioral and clinical data
from an annual probability sample of persons in care for HIV
infection in the United States. The goals of MMP are to provide
nationally representative estimates of clinical (quality of care,
access to and use of HIV care, treatment) and behavioral (use of
prevention services, medication adherence, and levels of ongoing
risk behaviors) outcomes among persons living with HIV infection.
To improve the quality and usefulness of data, MMP will increase
the representativeness of data compared to legacy systems; will
increase the relevance of data for use at the local level (e.g., for
Ryan White Comprehensive AIDS Resources Emergency
[CARE] and HIV prevention planning groups); and will collect
data from people through both interview and medical record
review.
This report describes the evolution of supplemental surveillance
for behaviors and clinical outcomes, articulates the rationale for
the development of this new supplemental HIV surveillance
system, briefly describes the MMP methods, and explains how
MMP is being used at the local and national levels.
A Brief History of HIV Behavioral and Clinical
Outcomes Surveillance
HIV and AIDS case reporting has been the underpinning of HIV/
AIDS surveillance activities since the mid-1980s [1]. All US states
have reported AIDS cases using a standard case definition since
1985 [2], and as of 2005, all states conduct surveillance for HIV
infection without AIDS [3]. Early in the epidemic, case
surveillance data were interpreted in the context of the natural
history of HIV infection: clinical disease or severe immunosup-
pression were predictably (if distantly) related to the time of HIV
infection, and AIDS trends accurately reflected past trends in HIV
infections [4]. However, as availability and prescription of highly
active antiretroviral therapy (HAART) increased, the interval
between HIV infection and opportunistic infection (OI) diagnosis
or development of severe immunosuppression became highly
variable [5]. Thus, case surveillance data on severe immunosup-
pression and AIDS-defining OI (AIDS-OI) diagnoses were no
longer sufficient for monitoring clinical outcomes of HIV infection.
The expansion of the AIDS case definition in 1993 also created
challenges for describing the clinical outcomes of HIV infection.
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complete, because diagnosis of an AIDS-OI was a required
element for meeting the AIDS case definition. In 1993, the AIDS
case definition was expanded to include CD4 count,200 cells/ml
as an AIDS-defining criterion [6]. CD4 count,200 cells/ml
usually precedes the diagnosis of an AIDS-OI, and most cases are
now reported based on this immunologic criterion [7]. For these
cases, subsequent AIDS-OI diagnoses are not systematically
documented in the case surveillance system. Thus, the complete-
ness of ascertainment of AIDS-OIs decreased considerably after
1993 [7,8].
In response to the limitations of HIV/AIDS case surveillance to
characterize the evolving epidemic, supplemental surveillance
systems were developed by the Centers for Disease Control and
Prevention (CDC) and state surveillance programs during the
1990s to address emerging data needs. The Adult/Adolescent
Spectrum of HIV Disease (ASD) project was implemented in 1990
to collect information on the natural history of HIV/AIDS, and
later evolved to include data on treatment and clinical outcomes
(e.g., AIDS-OIs, other illnesses, the impact of treatment and
prophylaxis) of people with HIV infection who were in care [9].
This facility-based, observational cohort study, which used
medical record reviews, operated in 11 US cities from 1990–
2004, and observed over 61,000 people in care for HIV infection.
ASD data were initially utilized to help determine allocation of
resources and to track clinical outcomes; later, to replace case
surveillance as the primary means to monitor trends in OIs; and
later still, to monitor treatment, survival, and outcomes in the
HAART era [10–18].
Similarly, the Supplement to HIV/AIDS Surveillance (SHAS)
project was implemented to collect behavioral information by
interview of people living with HIV infection. SHAS interviewed
people living with HIV infection from 1990 to 2004 in 19 states
and local areas, providing important information on HIV testing
and care-seeking behaviors, access to health care and ongoing sex
and drug use behaviors [19]. SHAS data have been used to inform
local planning processes and national reporting of behavioral
trends among person with HIV infection [20–27].
While ASD and SHAS each provided information useful for
understanding the epidemic in its various stages, limitations, such
as the lack of linked medical record and interview data, limited
number of areas participating, and lack of nationally representa-
tive estimates for HIV-infected patients in care, resulted in the
need for new systems to collect data on behaviors and clinical
outcomes [28].
The Need for a New, Population-Based Surveillance
Approach
A new surveillance approach was needed to understand the
clinical outcomes and behaviors of people in care for HIV
infection because of 3 main factors. First, the introduction of
HAART created new challenges for clinical outcomes surveillance.
Second, the HIV epidemic now severely impacts more geographic
areas in the US, and many people with HIV receive care outside
of the major cities where the epidemic–and supplemental
surveillance efforts–was centered in earlier years. Third, there
are increased needs for representative data to describe the
epidemic and related resource needs for care and treatment at
the local and national levels.
The introduction of HAART and related challenges Effec-
tive administration of HAART to persons living with HIV
infection delays the progression of immunosuppression and is
associated with decreased incidence of AIDS-OIs and death [29].
This development, after 1996, had significant implications for HIV
clinical outcomes surveillance. First, for those persons in care,
understanding the extent to which HAART is prescribed as
indicated in a variety of practice settings is critical to evaluating
our efforts to decrease the severity of HIV disease and to identi-
fying opportunities for improving clinical care and preventing
morbidity. Second, the understanding that very high levels of
adherence to HAART are required for acceptable suppression of
viral load makes the collection of correlated data from medical
records and interview a high priority to understand the acceptance
of and adherence to recommended antiretroviral therapies. Third,
following the availability of HAART, a dichotomy in clinical
outcomes for HIV infection has emerged: many persons with HIV
infection are living longer, resulting in a strain on available
treatment and care resources, while those who do not have timely
diagnosis of HIV continue to learn of their HIV infection status
only when they are clinically ill or late in the course of infection
[30–33]. It was important that MMP address multiple sub-
populations of people living with HIV infection, including those
receiving regular care and those who access care intermittently.
Finally, as the number of people living with HIV infection grows,
CDC, the Health Resources Services and Administration (HRSA),
and the Infectious Disease Society of America have published
guidelines for the provision of prevention services to HIV-positive
people [34]. There is a need to monitor the provision of these
services, and trends in transmission risk behaviors of people in care
for HIV infection.
Increased geographic heterogeneity of the HIV
epidemic There has been a great increase in the geographic
distribution of HIV-infected persons [35,36]. Previous supple-
mental surveillance projects were conducted mainly in large
metropolitan areas, which were most heavily impacted in the first
decade of the epidemic. There are two impacts of this diffusion of
HIV morbidity on surveillance requirements. First, it is important
to understand the clinical outcomes, quality of care, and related
behaviors in diverse settings where HIV care occurs. Quality of
care, and clinical outcomes, are related to physician experience in
HIV care [37]; in areas with lower morbidity and fewer specialty
practices, physician experience and other important factors may
vary. Second, more states have substantial morbidity and need
data on illnesses and behaviors of HIV-infected persons for local
planning and resource allocation for both prevention and care. In
1991, when the Ryan White Comprehensive AIDS Resource
Emergency (CARE) Act was first authorized and ASD and SHAS
began, there were 16 Eligible Metropolitan Areas (EMAs); in
2006, there were 51 EMAs [38]. Given the substantial expenditure
of federal and state funds on HIV care [39] and prevention, all
areas receiving Ryan White CARE Act support should have access
to the highest quality data for allocation and prioritization
purposes.
Increased needs for representative data to describe the
epidemic and resource needs, and to provide context for
existing observational data sources There are many existing
and previous cohorts that provide data on HIV-infected patients in
care in the United States, and these cohorts have made significant
contributions to our understanding of the natural history of HIV
infection and to treatment recommendations. Recently, progress
has been made to combine data from observational cohorts, in
order to facilitate more comprehensive datasets and to allow more
robust analyses. The North American AIDS Cohort Collaboration
on Research and Design (NA-ACCORD) has been established, as
part of the International Epidemiologic Databases to Evaluate
AIDS (IeDEA) initiative. NA-ACCORD represents over 70,000
HIV-infected patients in care in over 50 clinical sites in the major
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to NA-ACCORD and individual US clinical cohorts, by providing
a nationally representative view of the characteristics of HIV-
infected persons in care. MMP data will include patients recruited
from a greater diversity of practice settings–including between 800
and 1000 clinical sites each year–and will also include patients in
care outside of major metropolitan areas (Figure 1). Having
a representative sample of patients in care will provide a frame of
reference by which observational cohorts can characterize the
inclusion biases in their own populations, and may also be useful to
define a reference population, to which data from other cohorts
can be standardized in analyses. This may be important in
reporting outcomes which are significantly associated with race
and ethnicity, because previous CDC-supported studies and many
current facility-based cohort studies have racial/ethnic
distributions that are not necessarily reflective of the population
of adults living with HIV in the US (Table 1).
At the request of Congress, an Institute of Medicine (IOM)
committee in 2003 reviewed the status of HIV/AIDS surveillance
data and the extent to which data currently collected by the AIDS
case surveillance and supplemental surveillance systems were
adequate for determining allocation of resources for treatment and
care of HIV infection [41]. The IOM committee recommended
that HRSA and the CDC evaluate the cost and utility of
redesigning studies to assess the specific needs and circumstances
of people living with HIV. One of the approaches proposed by the
IOM was to coordinate HRSA and CDC efforts to survey
a random sample of HIV-infected persons to develop more
accurate measures of need for prevention and care services. These
recommendations are being met through the implementation of
MMP.
The Medical Monitoring Project: A Population-Based
Approach to Behavioral and Clinical Outcomes
Surveillance
CDC is working with state and local health departments to obtain
a national probability sample of patients in care for HIV infection.
The methods were developed in light of an earlier population-
based survey of persons in care for HIV infection [42,43], and
earlier CDC pilots of population-based methods [44].
The design is a three-stage sampling approach (Figure 2). The
first stage of sampling resulted in the selection of 20 of 52 eligible
geographic primary sampling units (PSUs, defined as 50 states,
Figure 1. Geographic distribution of US HIV clinical cohorts and Medical Monitoring Project data collection sites, 2007.
doi:10.1371/journal.pone.0000550.g001
Table 1. Racial/Ethnic Distribution of Adults
* Living with HIV/AIDS in the United States, 2003, and in US HIV Cohorts, 2003-2006
..................................................................................................................................................
Data Source N % White % Black % Hispanic % Other
US Case Reports
{ (2003) [59] 476,749 34 47 17 1
NA-ACCORD overall (range) [40] 71,598 (562-17,125) 46% (10%-65%) 39% (16%-90%) N/A{ N/A{
ASD (2003) 12,477 29 49 20 2
SHAS (2003) 2,371 22 54 20 4
*Aged 13 and older in ASD and the US living HIV/AIDS cases, 18 and older in SHAS
{Estimated number of persons living with HIV/AIDS at the end of 2003 from 33 areas with confidential name-based HIV infection reporting
{Not available: data on patients with Hispanic ethnicity are not reported in cohort profile [40]
doi:10.1371/journal.pone.0000550.t001
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PLoS ONE | www.plosone.org 3 June 2007 | Issue 6 | e550Washington, DC, and Puerto Rico) using probability proportional
to size (PPS) sampling methods. Sampling methods ensured
representation of all regions of the US (Figure 1). In the second
stage, providers of HIV care (i.e., providers that prescribe
antiretroviral therapy [ART] or order CD4 or HIV viral load
tests) are sampled. The sampling frame of providers is developed
in each participating geographic area using data from local HIV/
AIDS case surveillance, laboratory reporting, AIDS Drug
Assistance Programs and other available data sources. Providers
are sampled using PPS methods based on their patient caseload. In
the third stage, local HIV/AIDS surveillance staff work with each
selected provider to develop a list of HIV-infected patients who
received care from the provider at least once in the first four
months of the year. From this list, an equal probability sample of
patients is chosen [44].
Through an informed consent process, selected patients are
offered participation in an interview with the understanding that
their medical records will also be reviewed. The types of data
collected from the interview and medical record abstraction are
represented in Table 2. For most data elements, the interview and
medical record abstraction collect data pertaining to the 12 month
period prior to the interview date; a few important variables (e.g.,
prescription of antiretroviral therapy, diagnosis of an AIDS-OI)
are documented if they occurred ever following HIV diagnosis.
Sampled states have a minimum sample size of 400 patients; for
some states with large numbers of prevalent cases, higher sample
sizes are allocated (California, 1300; Florida, 800; Illinois, 500;
New Jersey, 500; New York, 1200; Pennsylvania, 500; Texas, 800).
The minimum sample size will allow the annual description of
outcomes of interest–for example, the proportion of eligible
patients prescribed prophylaxis for Pneumocystis jiroveci pneumonia–
with a confidence interval half-width of 6 4t o6 7% in individual
project areas (depending on total sample size in the area), and with
a confidence interval half-width of 6 1% in national data.
Data from pilot studies indicate that the differences in results of
population-based versus representative samples are meaningful.
Estimates from previous surveillance projects demonstrate differ-
ences in outcomes reported from population-based versus
convenience samples. When comparing the proportion of patients
treated according to guidelines in ASD and CDC’s Survey of HIV
Disease in Care (SHDC) project, the pilot of population-based
surveillance methods conducted beginning in 1998, differences
Figure 2. Medical Monitoring Project 3-stage sampling design.
doi:10.1371/journal.pone.0000550.g002
Table 2. Medical Monitoring Project Data Domains, 2007*
......................................................................
Collected by Interview Collected by Medical Record Abstraction
Demographics Demographics
Access to health care Insurance status
Adherence to antiretroviral therapy AIDS-defining and other illnesses
Unmet need Laboratory values
Sexual behavior Antiretroviral and other medications
prescribed
Drug and alcohol use history Substance abuse
Inpatient, outpatient and emergency
room visits
*Complete interview and chart abstraction instruments are available at: http://
www.cdc.gov/hiv/topics/treatment/MMP/index.htm
doi:10.1371/journal.pone.0000550.t002
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PLoS ONE | www.plosone.org 4 June 2007 | Issue 6 | e550were found [44]. In King County, Washington, estimates of
proportions of individuals with at least one CD4 or HIV viral load
test documented were higher in SHDC patients (95%, 95% CI 91-
100) than ASD patients (82%); the opposite was found in
Michigan (SHDC 68%, 95% CI 50-86; ASD 87%). This is likely
due to differences in the types of providers and facilities that
participated in these projects. MMP, being representative of
facility types, HIV-infected patient caseloads, and provider
experience and specialization will provide more accurate estimates
of HIV care and treatment parameters at both the local and
national levels.
Uses of Population-Based Behavioral and Clinical
Outcomes Data
Local Data Uses At the local level, MMP data will be useful for
local community planning purposes, including the development of
local epidemiologic profiles and responding to data requests from
agencies which provide resources for HIV care and treatment.
MMP will provide information on the characteristics of persons in
care for HIV infection and the types of care they are accessing,
and will identify needs for prevention and care services among
a representative sample of persons in care. Information about
access to and use of these services can inform the evaluation of
care and prevention services for people living with HIV.
MMP data will allow estimation of unmet need for HIV care
and services, and quality of HIV care provided; such estimates are
often required by funders of HIV treatment and care [45]. In an
effort to reduce the burden on local health jurisdictions and
improve comparability of data across reporting areas, HRSA and
CDC collaborated on the development of data elements for MMP,
and will work together to determine reporting plans that will
improve standardization of data collection methods.
A strategy to provide state-level estimates of important
behaviors and clinical outcomes using a probability sample will
change the quality of information available at the local level in two
ways. First, in almost all cases in the past, community planning
groups, CARE Act planning consortia and councils have utilized
data from projects which, because of recruitment methods, were
not necessarily representative of populations living with HIV in the
community. Data from a local probability sample would improve
the representativeness of the data available to planning groups.
Second, data available from past supplemental surveillance
projects have not generally been locally interpreted with
confidence intervals to reflect the uncertainty around point
estimates. MMP will provide planning bodies information about
the confidence with which estimates are made. It will be important
for CDC and state and local partners to provide training for
planning bodies and other users of MMP data to allow appropriate
interpretation of the data, and to understand how data available
from MMP compare to data from other local projects previously
used for local planning processes.
Historically, local areas and their planning bodies have sought
separate estimates for population subgroups (e.g., the proportion of
persons of color receiving HAART) or to perform statistical testing
for differences between subgroups (e.g., to determine if men and
women have differences in access to certain services). Although
a probability sample approach will allow for estimation of
outcomes for such subgroups and significance testing, a limitation
of the MMP design is that the numbers of patients represented in
some subgroups may be small at the local level. It is not likely that
sufficient power will be present for hypothesis testing among
subgroups within a project area in any single project year. Samples
drawn across successive years can be combined to gain additional
statistical power and to analyze data in smaller subgroups of
interest.
National Data Uses At the national level, MMP data will be
useful for tracking national trends in morbidity; for describing
service access and utilization; for focusing and prioritizing national
initiatives to improve the provision of treatment and prevention
resources; and for benchmarking and evaluating progress towards
national prevention and treatment objectives. Annual or bi-annual
national estimates of rates of OI diagnoses will be the gold
standard for measuring the effectiveness of reducing the severity of
HIV-related disease, for describing the characteristics of persons
who have progressive HIV disease, and for characterizing the
reasons for disease progression. Similarly, a nationally representa-
tive sample provides the ideal data source for evaluating progress
towards national public health goals, such as describing the
proportion of persons receiving appropriate care for HIV infection
as described by Healthy People 2010 targets [46]. CDC, HRSA
and other governmental agencies are also required to account for
use of resources to Congressional funders. For example the
Government Performance and Results Act (GPRA) requires
reporting of data on prevention of OIs, provision of prevention
services, and proportion of CARE Act clients receiving CD4
counts and viral loads [47]. National data should also be useful for
documenting the need for treatment resources. Data from the
MMP will be of the highest quality for answering national
questions about care and treatment needs, the quality of care and
treatment, and the use and impact of allocated resources.
Data from the interview portion of the project will also be
relevant to evaluation of prevention initiatives for persons living
with HIV infection, as described in the Advancing HIV Preven-
tion Initiative and as envisioned in HIV Prevention Strategic Plan
goals for reducing the number of people at risk for transmitting
HIV infection [48,49]. Data on key indicators of behavioral risks
for transmitting HIV will be available with national, population-
based inference, and can be used to determine progress towards
national goals and identify populations in need of additional
research, improved interventions, or additional funds to support
prevention programs.
There are some important limitations to MMP as a surveillance
system for clinical outcomes and related behaviors. Because MMP
does not have a longitudinal component, data from MMP cannot
evaluate outcomes such as survival and effects of therapy over
time; data from existing cohorts will be needed to evaluate these
outcomes [50–53]. The cost per patient recruited and enrolled is
greater for MMP than for facility-based studies, and therefore, it is
more difficult to obtain adequate sample sizes to make inference to
subgroups of interest, especially at the local level.
Security and Confidentiality
Historically, the legal authority for collecting and reporting data
on cases of infectious diseases, including HIV/AIDS, resides with
state and local governments [54]. Each state has its own unique
legislation, written rules, or regulations mandating the collection of
these types of data, and there is considerable variation between
jurisdictions [55]. These laws, rules, and regulations allow access
to patients’ medical records by the health departments for
purposes of conducting routine surveillance as part of their
mandate to protect the public’s health. Names of cases and other
unique identifiers collected are retained by state and local
jurisdictions and are never sent to CDC. All HIV/AIDS
surveillance data have protections at both the state and federal
levels. At the state level, state laws and regulations protect
surveillance information, limit the uses of data for non-public
health purposes, and provide criminal penalties for inappropriate
Improving HIV Surveillance
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surveillance data are held under the Federal Assurance of
Confidentiality, which protects data held by CDC from disclosure
for any purpose other than that for which it was collected [57]. In
many local areas, legal authority for HIV/AIDS surveillance
activities may also extend to the collection of clinical outcomes
surveillance data in MMP.
In April 2003, the Health Insurance Portability and Account-
ability Act (HIPAA) of 1996 was implemented and regulates how
covered entities (including most health care delivery organizations)
use and disclose certain individually identifiable health informa-
tion. Surveillance data are specifically exempted from HIPAA
because these data are required to be reported to the health
department by state and local laws [58]. Health departments
conducting MMP are public health authorities, as defined by
HIPAA, and many consider MMP to be a surveillance activity.
Health care providers may disclose protected health information
to public health authorities without individual authorization for
the purposes of preventing or controlling disease, for example, as
part of HIV/AIDS surveillance activities–including MMP [58].
Summary
There have been many changes in the HIV epidemic in the US
over the past two and a half decades. To address current
supplemental surveillance data needs, the reporting requirements
for entities providing direct funding for HIV care and prevention
services, and recent recommendations from the IOM, CDC and
its state and local health department partners have developed
a population-based probability sample approach to surveillance for
HIV-related behaviors and clinical outcomes, health care
utilization, and unmet needs in HIV-infected persons in care.
Primary products will be representative state- and national-level
estimates of important clinical outcomes of HIV infection,
resource utilization, compliance with treatment guidelines, and
behavioral outcomes. This approach promises to provide higher
quality information for prevention and care planning, resource
allocation and evaluation at the national and local levels.
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